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https://doi.org/10.1016/j.immuni.2020.12.002SUMMARYMemory T cell responses have been demonstrated in COVID-19 convalescents, but ex vivo phenotypes of
SARS-CoV-2-specific T cells have been unclear. We detected SARS-CoV-2-specific CD8+ T cells by MHC
class I multimer staining and examined their phenotypes and functions in acute and convalescent COVID-19.
Multimer+ cells exhibited early differentiated effector-memory phenotypes in the early convalescent phase.
The frequency of stem-like memory cells was increased among multimer+ cells in the late convalescent
phase. Cytokine secretion assays combined with MHC class I multimer staining revealed that the proportion
of interferon-g (IFN-g)-producing cells was significantly lower among SARS-CoV-2-specific CD8+ T cells than
those specific to influenza A virus. Importantly, the proportion of IFN-g-producing cells was higher in PD-1+
cells than PD-1 cells among multimer+ cells, indicating that PD-1-expressing, SARS-CoV-2-specific CD8+
T cells are not exhausted, but functional. Our current findings provide information for understanding of
SARS-CoV-2-specific CD8+ T cells elicited by infection or vaccination.INTRODUCTION
Coronavirus disease 2019 (COVID-19) is an ongoing pandemic
disease caused by infection with severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2). As of August 16, 2020,
more than 21 million confirmed cases and more than 760,000
deaths have been reported worldwide (World Health Organiza-
tion, 2020). COVID-19 is characterized by a broad spectrum of
clinical manifestations, ranging from asymptomatic or mild44 Immunity 54, 44–52, January 12, 2021 ª 2020 Elsevier Inc.illness to severe illness that requires hospitalization andmechan-
ical ventilation (Huang et al., 2020). To develop effective vac-
cines and establish appropriate therapeutic interventions for
patients with COVID-19, a better understanding of the immune
responses against SARS-CoV-2 is urgently needed.
In patients with COVID-19, the CD8+ T cell population un-
dergoes quantitative and qualitative changes. Lymphopenia pref-
erentially affects CD8+ T cells (Mathew et al., 2020; Mazzoni et al.,
2020), and low numbers of CD8+ T cells are found in severe
Figure 1. Ex Vivo Detection of SARS-CoV-2-Specific CD8+ T Cells Using MHC Class I Multimers
(A) Study scheme for the detection of SARS-CoV-2-specific MHC class I multimer+CD8+ T cells in PBMCs from individuals with SARS-CoV-2 infection.
(B) SARS-CoV-2-specific MHC class I multimers used in this study.
(C) Summary data for the detection rate of SARS-CoV-2-specific multimer+CD8+ T cells.
(D) Representative flow cytometry plots (S269, n = 37; S1220, n = 2) showing the ex vivo detection of SARS-CoV-2 S269 and S1220 multimer
+CD8+ T cells in the gate
of CD3+ T cells.
(E) Alignment of the amino acid sequences of SARS-CoV-2 S269 and S1220 peptides with other human coronaviruses.
See also Figure S1.
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Reportdiseases (Chenetal., 2020;Mazzoni etal., 2020). Inaddition,CD8+
T cells from the bronchoalveolar lavage fluid of severe and critical
patients exhibit a lack of dominant clones comparedwith patients
with mild COVID-19 (Liao et al., 2020). Several studies have
observed an increased frequency of CD38+HLA-DR+ activated
CD8+ T cells (Kuri-Cervantes et al., 2020; Mathew et al., 2020)
and reduced interferon-g (IFN-g) productionbyCD8+T cells (Maz-
zoni et al., 2020; Zheng et al., 2020b) in patientswithCOVID-19. In
addition, a number of studies have reported an exhausted pheno-
type of CD8+ T cells in severe disease, with increased expression
of inhibitory receptors, particularlyPD-1 (DeBiasi et al., 2020;Diao
et al., 2020; Song et al., 2020; Zheng et al., 2020a). However,
whether PD-1+CD8+ T cells are truly exhausted or activated in pa-
tients with COVID-19 is unclear.
Early studies report SARS-CoV-2-reactive CD8+ T cell re-
sponses in individuals with COVID-19 (Grifoni et al., 2020; Le
Bert et al., 2020; Weiskopf et al., 2020). Up to 70% of convales-
cent individuals presented detectable CD8+ T cell responses
following in vitro stimulation with SARS-CoV-2 overlapping
peptides (Grifoni et al., 2020). These studies utilized activation-
induced marker (e.g., 4-1BB) assays or stimulation-based func-
tional assays, such as IFN-g ELISpot assays and intracellular
cytokine staining, to detect SARS-CoV-2-reactive CD8+ T cell
responses (Grifoni et al., 2020; Le Bert et al., 2020; Weiskopf
et al., 2020).
However, these assays have inherent limitations for the proper
characterization of SARS-CoV-2-specific CD8+ T cells. Stimula-
tion-based functional assays cannot detect virus-specific CD8+
T cells that are not functioning, and phenotypes of CD8+
T cells can change during in vitro stimulation. The limitation of
stimulation-based functional assays can be overcome by usingmajor histocompatibility complex class I (MHC class I) multimer
techniques (Altman et al., 1996). A recent study has detected
SARS-CoV-2-specific CD8+ T cells using MHC class I multimers
and described their phenotypes (Sekine et al., 2020). However,
functional heterogeneity within the SARS-CoV-2-specific CD8+
T cell population has not been elucidated in acute and convales-
cent COVID-19 patients. For example, little information is known
as to whether PD-1+ cells among SARS-CoV-2-specific MHC
class I multimer+CD8+ T cells are functioning or exhausted.
In the present study, we detected SARS-CoV-2-specific CD8+
T cells usingMHC class I multimers and investigated their ex vivo
phenotypes in peripheral bloodmononuclear cells (PBMCs) from
acute and convalescent COVID-19 patients. We also performed
cytokine secretion assays (CSAs) combined with MHC class I
multimer staining for ex vivo functional analysis of SARS-CoV-
2-specific CD8+ T cells. Our current analysis provides informa-
tion that is required for understanding of SARS-CoV-2-specific
CD8+ T cells elicited by infection or vaccination.
RESULTS
MHC Class I Multimer Staining Identifies a Dominant
CD8+ T Cell Epitope in SARS-CoV-2
We recruited a multicenter cohort comprised of 235 patients with
SARS-CoV-2 infection, including 120 who were HLA-A*02(+).
After excluding 4 patients due to a shortage of PBMC specimens,
we analyzed PBMCs from 116 HLA-A*02(+) patients. Serial blood
samples from the acute to convalescent phase were collected
from 21 of these patients, and a single blood sample was taken
in the acute phase from 7 patients and in the convalescent phase
from 88 patients (Figure 1A). We used eight commerciallyImmunity 54, 44–52, January 12, 2021 45
(legend on next page)
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Reportavailable HLA-A*02 multimers for the detection of SARS-CoV-2-
specific CD8+ T cells: six for spike (S) protein, one for membrane
(M) protein, and one for nucleocapsid (N) protein (Figure 1B).
SARS-CoV-2 S269 (YLQPRTFLL) multimer
+ cells were detected
in 37 of 112 (33.04%) patients, and SARS-CoV-2 S1220 (FIA-
GLIAIV) multimer+ cells in 2 of 40 (5.0%) patients (Figures 1C
and 1D). The demographic and clinical characteristics of the pa-
tients with multimer+ cells are presented in Table S1. However,
multimer+ cells were undetectable when staining the other MHC
class I multimers (Figure 1C). We found that SARS-CoV-2 S269
and S1220 had a low degree of homology to the sequences of hu-
man common cold coronaviruses, including OC43, HKU1, 229E,
and NL63 (Figure 1E). The S269 epitope was specific to SARS-
CoV-2, whereas the S1220 epitope was conserved in SARS-
CoV-1 (Figure 1E). SARS-CoV-2 S269 or S1220 MHC class I
multimer+ cells were not detected in PBMCs from HLA-A*02(+)
subjects without SARS-CoV-2 infection (Figure S1).
SARS-CoV-2-Specific CD8+ T Cells Are Mainly Effector
Memory Cells in the Convalescent Phase
We examined the ex vivo phenotypes of SARS-CoV-2 S269 MHC
class I multimer+CD8+ T cells in PBMCs from convalescent indi-
viduals by assessing the expression of the chemokine receptor
CCR7 and CD45RA. MHC class I multimer+ cells predominantly
exhibited an effector memory (CCR7CD45RA) phenotype,
and roughly 25% of MHC class I multimer+ cells were terminally
differentiated effector (CCR7CD45RA+) cells (Figures 2A
and S2). Some patients had a considerable proportion of
CCR7+CD45RA+ cells among the MHC class I multimer+ cells,
which may indicate the presence of CD8+ stem-like memory
T cells (Gattinoni et al., 2011).
During viral infection, CD127 and KLRG1 have been used as
markers to identify effector CD8+ T cell subsets with distinct fea-
tures regarding long-term survival and effector function (Chang
et al., 2014). We found that the majority of MHC class I multimer+
cells from convalescent individuals were CD127KLRG1 cells
(Figures 2A and S2). In addition, a considerable proportion
of MHC class I multimer+ cells were CD127KLRG1+ and
CD127+KLRG1 cells, whereas CD127+KLRG1+ cells were
rarely observed (Figures 2A and S2).
The expression of CD28 is particularly useful in distinguishing
between subsets of differentiated CD8+ T cells (Appay et al.,
2002). The MHC class I multimer+ cells in our cohort were largely
CD28+ cells, suggesting that these cells are early differentiated
cells (Figures 2A and S2). When we examined T cell exhaustion
and activation markers, the frequencies of PD-1+, CD38+, andFigure 2. Phenotypes of SARS-CoV-2-Specific Multimer+CD8+ T Cells
(A–H) PBMCs from convalescent patients were analyzed by flow cytometry.
(A) Representative flow cytometry plots (n = 32) showing the percentages of indi
(B and C) The frequency of SARS-CoV-2 S269 multimer
+CD8+ T cells among tota
CoV-2 S269 multimer
+CD8+ T cells (C) in the early convalescent samples were co
(D and E) The frequency of SARS-CoV-2 S269 multimer
+CD8+ T cells among tota
CoV-2 S269 multimer
+CD8+ T cells (E) were compared between the early (n = 19
(F) Correlation between the expression of the indicated markers in SARS-CoV-2
(G and H) The phenotypes of SARS-CoV-2 S269 multimer
+CD8+ T cells (early con
those of IAV MP58 multimer
+CD8+ T cells (n = 11; 3 HDs and 8 convalescent indiv
late convalescent phase, n = 13; IAV, n = 11) (G) and summary data (H) of the pe
Data are presented as median and interquartile range (IQR). Statistical analysi
correlation test (F). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also FHLA-DR+ cells among MHC class I multimer+ cells were approx-
imately 20%, 25%, and 10%, respectively (Figures 2A and S2).
We classified the convalescent PBMC samples into two
groups, ‘‘early convalescent’’ and ‘‘late convalescent’’, obtained
within and after the first 14 days following the negative conver-
sion of viral RNA in nasopharyngeal swab specimens, respec-
tively. First, we analyzed the early convalescent samples and
compared the frequency and phenotype of MHC class I
multimer+ cells between the two groups according to disease
severity (n = 11 non-severe and n = 8 severe). The severe group
had a significantly higher frequency of MHC class I multimer+
cells among CD8+ T cells than the non-severe group (Figure 2B).
The frequency of CD127+KLRG1- and CD28+ cells among MHC
class I multimer+ cells was significantly lower in the severe group
than the non-severe group (Figure 2C).
Stem-like Memory Cells Are Increased among SARS-
CoV-2-Specific CD8+ T Cells in the Late
Convalescent Phase
Next, we compared the frequency and phenotype of MHC class I
multimer+ cells between the early convalescent and late conva-
lescent samples. The frequency of MHC class I multimer+ cells
among CD8+ T cells was higher in the early convalescent sam-
ples than the late convalescent samples (Figure 2D). The per-
centage of CCR7+CD45RA+ cells tended to be higher in the
late convalescent samples, whereas the percentage of
CCR7CD45RA cells was significantly decreased (Figure 2E).
In addition, the frequency of CD127+KLRG1 cells among
MHC class I multimer+ cells was significantly increased in the
late convalescent samples, whereas the frequency of
CD127KLRG1 cells was decreased (Figure 2E). We also
observed that the expression of PD-1 and CD38 in MHC class
I multimer+ cells was lower in the late convalescent samples
compared to the early convalescent samples (Figure 2E).
When we investigated the correlation between phenotypes of
MHC class I multimer+ cells and days post-symptom onset,
the percentage of CCR7+, CD45RA+, and CD127+ cells among
MHC class I multimer+ cells positively correlated with the timing
(Figure 2F), indicating that stem-like memory CD8+ T cells may
be generated in the late convalescent phase. Furthermore, we
observed an inverse correlation between the expression of
PD-1 and CD38 in MHC class I multimer+ cells and days post-
symptom onset (Figure 2F).
We further compared SARS-CoV-2-specific CD8+ T cells with
influenza A virus (IAV)-specific CD8+ T cells in terms of the differ-
entiation phenotype. The IAV-specific CD8+ T cell populationin the Convalescent Phase of COVID-19
cated subsets among SARS-CoV-2 S269 multimer
+CD8+ T cells.
l CD8+ T cells (B) and the percentages of the indicated subsets among SARS-
mpared between the non-severe (n = 11) and severe (n = 8) groups.
l CD8+ T cells (D) and the percentages of the indicated subsets among SARS-
) and late (n = 13) convalescent groups.
S269 multimer
+CD8+ T cells and days post-symptom onset (n = 30).
valescent phase, n = 19; late convalescent phase, n = 13) were compared with
iduals). Representative flow cytometry plots (early convalescent phase, n = 19;
rcentages of all indicated subsets among CD8+ T cells specific for each virus.
s was performed using the Mann–Whitney U test (B–E and H) or Spearman
igure S2.
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Figure 3. Proliferation and Effector Function of SARS-CoV-2-Specific CD8+ T Cells from Convalescent Patients
(A) CTV-labeled PBMCs from convalescent COVID-19 patients (n = 6) were stimulated with S269 peptide (10 mg/mL) for 7 days and analyzed by flow cytometry.
Flow cytometry plots show the frequency of CTVlow cells among SARS-CoV-2 S269 multimer
+CD8+ T cells.
(legend continued on next page)
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Report(n = 11; 3 healthy donors [HDs] and 8 convalescent patients) had
more CD127+KLRG1 and CCR7CD45RA cells than the
SARS-CoV-2-specific CD8+ T cell population from both early
(n = 19) and late (n = 13) convalescent samples (Figures 2G
and 2H). In contrast, the frequency of CCR7+CD45RA+ cells
was higher in SARS-CoV-2-specific CD8+ T cells from the late
convalescent samples compared with IAV-specific CD8+
T cells (Figures 2G and 2H). The expression of PD-1 tended to
be lower in IAV-specific CD8+ T cells compared with SARS-
CoV-2-specific CD8+ T cells from early convalescent samples,
but the difference was not significant (Figures 2G and 2H).
PD-1-Expressing SARS-CoV-2-Specific CD8+ TCells Are
Not Exhausted but Functional
To evaluate the memory response of CD8+ T cells following res-
olution of the infection, we analyzed the proliferative capacity of
SARS-CoV-2-specific CD8+ T cells from convalescent patients.
PBMCs from convalescent patients were stimulated with
S269 peptide, and the proliferation of SARS-CoV-2 S269
multimer+CD8+ T cells was evaluated by CellTrace Violet (CTV)
dilution assays. We confirmed that SARS-CoV-2 S269-specific
memory CD8+ T cells have the capacity to proliferate upon anti-
genic re-challenge regardless of the disease severity (Figure 3A).
Next, we investigated IFN-g production from SARS-CoV-2-
specific MHC class I multimer+CD8+ T cells. We stimulated
PBMCs from convalescent patients with S269 peptide ex vivo
and performed CSAs with SARS-CoV-2 S269 multimer staining
for simultaneous analysis of the phenotype and function of
virus-specific T cells (Park et al., 2012). Comparing IFN-g produc-
tion by SARS-CoV-2-specific CD8+ T cells from individuals in the
early convalescent phase and CD8+ T cells specific for IAV or
cytomegalovirus (CMV) from convalescent individuals or HDs,
we found that the proportion of IFN-g-producing cells was signif-
icantly lower in SARS-CoV-2multimer+ cells than in IAVmultimer+
cells (n = 7 versus n = 7 and n = 7, IAV [2 HDs and 5 convalescent
patients] and CMV [4 HDs and 3 convalescent patients], respec-
tively; Figures 3B and 3C). We also observed that the proportion
of IFN-g+ cells tended to be lower in SARS-CoV-2 multimer+ cells
from the late convalescent samples comparedwith IAVmultimer+
cells (Figures 3B and 3C). In addition, we found no significant dif-
ferences in the frequency of IFN-g-producing cells among SARS-
CoV-2 multimer+ cells between early convalescent samples from
the severe group and those from the non-severe group or be-
tween the early convalescent and late convalescent samples (Fig-
ures 3B and 3C).
Because a considerable proportion of the SARS-CoV-2-spe-
cific multimer+CD8+ T cell population expressed PD-1 (Figures(B–E) PBMCs were stimulated with SARS-CoV-2 S269 peptide (n = 10; 3 early conv
severe disease, and 3 late convalescent samples), CMV pp65495 peptide (n = 7; 4
convalescent individuals). The concentration of each peptide was 1 mg/mL. Afte
multimer staining to analyze the frequency of IFN-g-producing cells among MHC
samples with non-severe disease, n = 3; early convalescent samples with severe
data (C) are presented. Horizontal lines represent the median. (D) Representative
IFN-g-producing cells among PD-1+ and PD-1 subpopulations of SARS-CoV-2
(F and G) Sorted PD-1+CD8+ and sorted PD-1CD8+ T cells from PBMCs of COVI
for 5.5 h and CSAs performed in combination with MHC class I multimer staining.
the frequency of IFN-g-producing cells in the SARS-CoV-2 S269 multimer
+CD8+
Statistical analysis was performed using the Mann–Whitney U test (C) or the Wilc2A and S2), we investigated whether IFN-g was produced by
PD-1+ or PD-1 cells among SARS-CoV-2-specific multimer+
CD8+ T cells. The proportion of IFN-g-producing cells was signif-
icantly higher in PD-1+ cells than in PD-1 cells regardless of
disease severity (Figures 3D and 3E). To confirm this result, we
performed IFN-gCSAs after sorting PD-1+CD8+ and PD-1CD8+
T cells. MHC class I multimer+ cells among sorted PD-1+CD8+
T cells, as well as those among sorted PD-1CD8+ T cells, pro-
duced IFN-g (Figures 3F and 3G). These findings demonstrate
that PD-1-expressing SARS-CoV-2-specific MHC class I
multimer+ cells are not exhausted but functional in patients
with COVID-19.
Frequency and Phenotypes of SARS-CoV-2-Specific
CD8+ T Cells Change during Viral Clearance in the
Acute Phase
Next, we examined the phenotype of SARS-CoV-2-specific
multimer+CD8+ T cells in the acute phase of COVID-19.
Multimer+ cells from patients in the acute phase exhibited an
activated phenotype with high expression of CD38, HLA-DR,
and PD-1 (Figure 4A). Almost all of the multimer+ cells expressed
cytotoxic molecules, including perforin and granzyme B (Fig-
ure 4A). In addition, the proliferation marker Ki-67 was highly
expressed in multimer+ cells in the acute phase, whereas
CD127, a marker of memory precursor cells, was rarely ex-
pressed (Figure 4A).
We also studied the kinetics of the ex vivo phenotypes of
SARS-CoV-2-specific multimer+CD8+ T cells during the course
of COVID-19. Viral titer measured by real-time reverse-transcrip-
tion (RT)-PCR detection of the SARS-CoV-2 viral genome in
nasopharyngeal swab samples tended to decrease over time
(Figure 4B). In addition, the frequency of multimer+ cells among
total CD8+ T cells tended to follow the viral titer kinetics
(Figure 4B). The proportions of Ki-67+ proliferating cells and
CD38+HLA-DR+ activated cells amongmultimer+ cells paralleled
changes in the frequency of multimer+ cells (Figure 4B). Howev-
er, the proportions of perforin+granzyme B+ cells and PD-1+ cells
among multimer+ cells tended to be sustained during the course
of COVID-19 (Figure 4B).
Finally, we performed CSAs with MHC class I multimer staining
to examine which subpopulations of multimer+ cells produce
IFN-g in the acute phase. Within the SARS-CoV-2-specific
multimer+CD8+ T cell population, IFN-g+ cells were more
frequently observed among PD-1+ cells compared with PD-1
cells (Figures 4C and 4D). In the analysis with activation markers,
IFN-gwas also producedmainly by CD38+ or HLA-DR+ cells (Fig-
ures 4C and 4D). These data indicate that IFN-g is produced byalescent samples with non-severe disease, 4 early convalescent samples with
HDs and 3 convalescent individuals), or IAV MP58 peptide (n = 7; 2 HDs and 5
r 5.5 h of stimulation, CSAs were performed in combination with MHC class I
class I multimer+ cells. Representative flow cytometry plots (early convalescent
disease, n = 4; late convalescent samples, n = 3; IAV, n = 7) (B) and summary
flow cytometry plots (n = 10) and (E) summary data showing the frequency of
S269 multimer
+CD8+ T cells from convalescent COVID-19 patients.
D-19 patients (n = 3) were stimulated with SARS-CoV-2 S269 peptide (1 mg/mL)
Representative flow cytometry plots (n = 3) (F) and summary data (G) showing
T cell population among sorted PD-1+ and PD-1CD8+ T cells.
oxon signed-rank test (E). **p < 0.01.
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Figure 4. Phenotypes, Kinetics, and Effector Function of SARS-CoV-2-Specific Multimer+CD8+ T Cells in the Acute Phase of COVID-19.
(A) PBMCs from patients in the acute phase of COVID-19 (n = 10) were analyzed by flow cytometry. Left, Representative flow cytometry plots (n = 10). Right,
summary data for the expression of indicated markers in SARS-CoV-2 S269 multimer
+CD8+ T cells. Data are presented as median and IQR.
(B) The frequency and phenotypes of SARS-CoV-2-specific CD8+ T cells were examined during the course of SARS-CoV-2 infection in seven patients (P5, P15,
P18, P74, and P76, severe disease; P12, non-severe disease; and P11, non-severe, asymptomatic). Viral titers (Ct values) were determined by real-time RT-PCR
of RdRP (P5, P15, P18, P74, P76, and P12) or N (P11) genes in specimens from nasopharyngeal swabs serially obtained during the course of COVID-19. The viral
titer and frequency of SARS-CoV-2 S269 multimer
+ cells among total CD8+ T cells were plotted against days post-symptom onset (P5, P15, P18, P74, P76, and
P12) or days post-admission (P11). The percentages of Ki-67+ (orange), perforin+granzyme B+ (blue), CD38+HLA-DR+ (pink), and PD-1+ (dark red) cells among
multimer+ cells are presented.
(C and D) PBMCs from P5 (14 days post-symptom onset), P12 (16 days post-symptom onset), P15 (15 days post-symptom onset), P74 (19 days post-symptom
onset), and P76 (17 days post-symptom onset) were stimulated with S269 peptide (1 mg/mL) for 5.5 h and CSAs performed in combination with MHC class I
multimer staining to analyze the phenotypes of IFN-g-producing cells among MHC class I multimer+ cells. Representative flow cytometry plots (n = 5) (C) and
summary data (D) show IFN-g production according to the expression of PD-1, CD38, and HLA-DR in the gate of multimer+ cells.
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Reportactivated SARS-CoV-2-specific CD8+ T cells, and that PD-1-ex-
pressing SARS-CoV-2-specific CD8+ T cells are activated func-
tioning cells, not exhausted cells, in the acute phase of COVID-19.
DISCUSSION
In the present study, we utilized an MHC class I multimer
technique to detect SARS-CoV-2-specific CD8+ T cells and50 Immunity 54, 44–52, January 12, 2021investigated the ex vivo phenotypes and function of SARS-
CoV-2-specific CD8+ T cells in combination with CSAs in the
acute and convalescent phases of COVID-19. Notably,
SARS-CoV-2-specific memory CD8+ T cells from convalescent
patients exhibited a high proliferative capacity, but IFN-g was
produced by less than half of the SARS-CoV-2-specific mem-
ory CD8+ T cell population. We also demonstrated that PD-1-
expressing SARS-CoV-2-specific CD8+ T cells from acute and
ll
Reportconvalescent patients were not exhausted, but activated and
functional.
A key feature of T cell exhaustion is loss of effector function
with sustained expression of inhibitory receptors (McLane
et al., 2019; Wherry and Kurachi, 2015). However, inhibitory
receptors are also upregulated in effector CD8+ T cells by
T cell receptor-induced activation (Singer et al., 2016; Wherry
and Kurachi, 2015). Although many studies have suggested ex-
hausted phenotypes of CD8+ T cells on the basis of increased
PD-1 expression in patients with COVID-19 (De Biasi et al.,
2020; Song et al., 2020; Zheng et al., 2020a; Zheng et al.,
2020b), whether CD8+ T cells truly become exhausted remains
controversial. In the current study, we demonstrated that
PD-1+ cells are not dysfunctional in the acute or convalescent
phase of COVID-19. From these results, we conclude that the
PD-1 expression on CD8+ T cells likely reflects activation, rather
than exhaustion, in COVID-19.
Another gap in our current understanding is how T cell memory
forms in patients who experience mild versus severe COVID-19.
In the current study, we found that the frequency of
CD127+KLRG1 cells, which are known as memory-precursor
effector cells during viral infection and able to differentiate into
multiple memory cell lineages (Chang et al., 2014; Kaech and
Wherry, 2007), among SARS-CoV-2-specific CD8+ T cells was
significantly lower in individuals who recently recovered from
severe disease than those who recovered from mild disease.
These data indicate that there may be differences in CD8+
T cell memory formation between patients who experienced
mild versus severe COVID-19. Whether the generation of long-
term memory CD8+ T cells is influenced by disease severity dur-
ing the acute phase of COVID-19 remains to be investigated.
Currently, many efforts are underway to develop prophylactic
vaccines against SARS-CoV-2 by inducing neutralizing anti-
bodies and memory T cells. However, the phenotypes of vac-
cine-induced, SARS-CoV-2-specific memory CD8+ T cells
have not been investigated. Previously, MHC class I multimers
were used to extensively examine the phenotypes and functions
of vaccine-induced, virus-specific memory CD8+ T cells in a
chimpanzee model of hepatitis C virus infection (Park et al.,
2012; Shin et al., 2013). In this model, vaccine-induced memory
CD8+ T cells exhibited higher CD127 expression and polyfunc-
tionality than infection-induced memory CD8+ T cells (Park
et al., 2012). In the current study, we found that the SARS-
CoV-2-specific memory CD8+ T cell population from convales-
cent patients exhibited low CD127 expression and had a low
frequency of IFN-g-producing cells. These findings indicate
that memory CD8+ T cells generated during natural infection
may have suboptimal responses against re-infection; thus,
vaccination may be required to develop effective T cell memory.
In summary, we characterized the immunological features
of SARS-CoV-2-specific CD8+ T cells in acute and convales-
cent COVID-19 patients. Our data provide insights into
SARS-CoV-2-specific CD8+ T cell responses and CD8+
T cell memory in the acute and convalescent phases of
COVID-19. Given that CD8+ T cells act as cardinal sentinels
against viral infections, these results may fill gaps in current
knowledge for the development of prophylactics and thera-
peutics against SARS-CoV-2 infection and for controlling the
current COVID-19 pandemic.Limitations of Study
Caveats of this study include the relatively low sample size.
While we screened a total of 235 individuals with COVID-19,
larger cohorts are needed to obtain clear results. Herein, we
suggest the evolution of SARS-CoV-2-specific CD8+ T cells
into stem-like memory cells in the late convalescent phase.
However, it needs to be confirmed by definitive markers of
stem-like memory cells, including CD95. In addition, future
studies with long-term follow-up of COVID-19 convalescents
would be required for a better comparison between
SARS-CoV-2-specific memory T cells and memory T cells
specific to other viruses. Our study relies on MHC class I mul-
timers specific to HLA-A*02-restricted epitopes in S protein.
However, CD8+ T cells specific to other SARS-CoV-2 proteins
and epitopes restricted by other HLA class I allotypes might
differ in phenotypes and function, which should be addressed
in further studies.STAR+METHODS
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ReportSTAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
BV510 anti-human CD3 (clone UCHT1) BD Biosciences Cat# 563109; RRID: AB_2732053
BV605 anti-human CD8 (clone SK1) BD Biosciences Cat# 564116; RRID: AB_2744466
BV421 anti-human CD127 (clone HIL-7R-M21) BD Biosciences Cat# 562436; RRID: AB_11151911
V450 anti-human Granzyme B (clone GB11) BD Biosciences Cat# 561151; RRID: AB_10565977
AF700 anti-human CD38 (clone HIT2) BD Biosciences Cat# 560676; RRID: AB_1727472
BB515 anti-human CD38 (clone HIT2) BD Biosciences Cat# 564498; RRID: AB_2744374
PE-CF594 anti-Human CD19 (clone HIB19) BD Biosciences Cat# 562294; RRID: AB_11154408
BB515 anti-human CD45RA (clone HI100) BD Biosciences Cat# 564552; RRID: AB_2738841
PerCP-Cy5.5 anti-human CCR7 (clone 150503) BD Biosciences Cat# 561144; RRID: AB_10562553
FITC anti-human HLA A2 (clone BB7.2) BD Biosciences Cat# 551285; RRID: AB_394130
PerCP-Cy5.5 anti-human HLA-DR (clone L243) BioLegend Cat# 307630; RRID: AB_893567
APC-Cy7 anti-human HLA-DR (clone L243) BioLegend Cat# 307618; RRID: AB_493586
BV785 anti-human CD28 (clone CD28.2) BioLegend Cat# 302950; RRID: AB_2632607
PE anti-human PD-1 (clone EH12.2H7) BioLegend Cat# 329906; RRID: AB_940483
APC-Cy7 anti-human CD127 (clone A019D5) BioLegend Cat# 351348; RRID: AB_2629572
AF700 anti-human Ki-67 (clone Ki-67) BioLegend Cat# 350530; RRID: AB_2564040
BV785 anti-human TIM-3 (clone F38-2E2) BioLegend Cat# 345032; RRID: AB_2565833
PE-eFluor 610 anti-human CD14 (clone 61D3) Thermo Fisher Scientific Cat# 61-0149-42; RRID: AB_2574534
PE-Cy7 anti-human KLRG1 (clone 13F12F2) Thermo Fisher Scientific Cat# 25-9488-42; RRID: AB_2573546
PE-Cy7 anti-human Perforin (clone dG9) Thermo Fisher Scientific Cat# 25-9994-42; RRID: AB_2573574
Biological Samples






Seoul Medical Center, Ansan
Hospital
N/A
Chemicals, Peptides, and Recombinant Proteins
Lymphocyte separation medium Corning Cat# 25-072-CV
Fetal bovine serum Corning Cat# 35-015-CV
Dimethyl sulfoxide Sigma-Aldrich Cat# D8418
7-AAD BD Biosciences Cat# 559925
SARS-CoV-2 S269-277 YLQPRTFLL peptide Mimotopes Customized
CMV pp65495-503 NLVPMVATV peptide Peptron Customized
Influenza A MP58-66 GILGFVFTL peptide Peptron Customized
Critical Commercial Assays
LIVE/DEAD red fluorescent reactive dye Invitrogen Cat# L34972
Celltrace Violet Invitrogen Cat# C34557
IFN-g Secretion Assay-Detection Kits, human Miltenyi Biotec Cat# 130-090-433
CD8 MicroBeads, human Miltenyi Biotec Cat# 130-045-201
FoxP3 staining buffer kit Invitrogen Cat# 00-5523-00
Software and Algorithms
FlowJo software version 10.7 FlowJo LLC https://www.flowjo.com/
(Continued on next page)
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Prism version 8 Graphpad https://www.graphpad.com/
MUSCLE Edgar 2004 N/A
Other
APC YLQPRTFLL (SARS-CoV-2 S269) HLA-A*0201 Pentamer Proimmune Cat# 4339
APC FIAGLIAIV (SARS-CoV-2 S1220) HLA-A*0201 Pentamer Proimmune Cat# 4321
APC RLQSLQTYV (SARS-CoV-2 S1000) HLA-A*0201 Pentamer Proimmune Cat# 4358
APC LITGRLQSL (SARS-CoV-2 S996) HLA-A*0201 Pentamer Proimmune Cat# 4323
APC ALNTLVKQL (SARS-CoV-2 S958) HLA-A*0201 Pentamer Proimmune Cat# 4322
APC RLNEVAKNL (SARS-CoV-2 S1185) HLA-A*0201 Dextramer Immudex Customized
APC TLACFVLAAV (SARS-CoV-2 M61) HLA-A*0201 Dextramer Immudex Customized
APC LLLDRLNQL (SARS-CoV-2 N22) HLA-A*0201 Dextramer Immudex Customized
APC NLVPMVATV (CMV pp65495) HLA-A*0201 Dextramer Immudex Cat# WB2132




Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Eui-Cheol
Shin (ecshin@kaist.ac.kr).
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
The published article includes all data generated during this study. All codes are freely available at source.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patients and Specimens
In this study, 235 patients diagnosed with SARS-CoV-2 infection were enrolled from Chungbuk National University Hospital, Sam-
sung Medical Center, Severance Hospital, Wonju Severance Christian Hospital, Seoul National University Bundang Hospital, Seoul
Medical Center, and Ansan Hospital. Peripheral blood (PB) was obtained from all patients with SARS-CoV-2 infection. SARS-CoV-2
RNA was detected in specimens from the patients’ nasopharyngeal swabs by multiplex real-time RT-PCR using the Allplex 2019-
nCoV Assay kit (Seegene, Seoul, Republic of Korea) or PowerCheck 2019-nCoV RT PCR kit (KogeneBiotech, Seoul, Republic of
Korea). In this assay, the E, N, and RdRP genes of SARS-CoV-2 were amplified and Ct values obtained for each gene. In the present
study, we categorized patients into two groups: non-severe and severe. Non-severe patients comprised asymptomatic, mild, and
moderate illness, whereas severe patients comprised severe and critical illness as defined by the NIH severity of illness categories
(National Institutes of Health, 2020). The convalescent phase was defined as the period after the negative conversion of SARS-CoV-2
RNA in real-time RT-PCR. The early and late convalescent phases were defined as the period within and after the first 14 days
following the negative conversion of SARS-CoV-2 RNA, respectively. PB was also obtained from 7 healthy donors without exposure
to SARS-CoV-2. This study was reviewed and approved by the institutional review board of all participating institutions and conduct-
ed according to the principles of the Declaration of Helsinki. Informed consent was obtained from all donors and patients.
PBMCswere isolated by density gradient centrifugation using Lymphocyte SeparationMedium (Corning, NY, USA). After isolation,
the cells were cryopreserved in fetal bovine serum (Corning) with 10% dimethyl sulfoxide (Sigma-Aldrich, St. Louis, USA) until use.
METHOD DETAILS
MHC class I multimer staining and multi-color flow cytometry
PBMCs were stained with APC-conjugated MHC class I multimers for 15 min at room temperature, washed, and then stained with
fluorochrome-conjugated antibodies for specific surface markers for 10 min at room temperature. Dead cells were excluded using
LIVE/DEAD red fluorescent reactive dye (Invitrogen, Carlsbad, CA, USA). In some experiments, cells were fixed and permeabilized
using the FoxP3 staining buffer kit (Invitrogen), and then stained for intracellular markers for 30 min at 4C.Multi-color flow cytometry
was performed using an LSR II instrument (BD Biosciences, San Jose, CA, USA) and the data analyzed in FlowJo software (FlowJoe2 Immunity 54, 44–52.e1–e3, January 12, 2021
ll
ReportLLC, Ashland, OR, USA). The fluorochrome-conjugated MHC class I multimers and monoclonal antibodies used in this study are
listed in the KEY RESOURCES TABLE.
Sequence alignment
Complete protein sequences for the spike protein of SARS-CoV-2 and other coronaviruses known to infect humans were
downloaded from the NCBI database (NCBI database: YP_009724390.1, YP_009825051.1, YP_009047204.1, YP_009555241.1,
YP_173238.1, NP_073551.1, YP_003767.1). MUSCLE algorithm (Edgar, 2004) was used to align multiple sequences.
Cell sorting
CD8+ T cells were enriched from PBMCs using magnetic-activated cell sorting CD8 microbeads (Miltenyi Biotec, Auburn, CA, USA)
according to the manufacturer’s instructions. Enriched CD8+ T cells were stained with PE-conjugated anti-PD-1 antibody (Bio-
Legend, San Diego, CA, USA) and 7-AAD (BD Biosciences), and then live PD-1+CD8+ and PD-1-CD8+ T cells were sorted using
an ARIA II instrument (BD Biosciences).
Cytokine secretion assay
PBMCs, sorted PD-1+CD8+ T cells, or sorted PD-1-CD8+ T cells were stained with APC-conjugated multimers for 15 min at room
temperature, washed, and stimulated with 1 mg/mL epitope peptide for 5.5 h. In experiments with sorted PD-1+CD8+ T cells or
PD-1-CD8+ T cells, autologous CD8- cells were used as feeder cells. After subsequent incubation with IFN-g catch reagents (Miltenyi
Biotec) for 55 min at 37C on a rotator, the cells were stained with FITC-labeled anti-IFN-g detection reagents (Miltenyi Biotec) for
10 min on ice. Additional staining was performed with APC-conjugated multimers and antibodies for specific surface markers.
Proliferation assay
PBMCs were stained with a cell division tracking dye, CTV (Invitrogen), according to the manufacturer’s instructions. CTV-labeled
cells were then stimulated with 10 mg/mL peptide for 7 days. On day 7, the cells were stained with MHC class I multimers and
proliferation assessed by flow cytometry.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 8 for Windows (GraphPad Software, San Diego, CA, USA).
Significance was set at p < 0.05. The Wilcoxon signed-rank test was used to compare data between two paired groups and the
Mann–Whitney U test to compare data between two unpaired groups. To assess the significance of correlation, the Spearman
correlation test was used.Immunity 54, 44–52.e1–e3, January 12, 2021 e3
